Literature DB >> 24464824

A deadly organometallic luminescent probe: anticancer activity of a ReI bisquinoline complex.

Igor Kitanovic1, Suzan Can, Hamed Alborzinia, Ana Kitanovic, Vanessa Pierroz, Anna Leonidova, Antonio Pinto, Bernhard Spingler, Stefano Ferrari, Roberto Molteni, Andreas Steffen, Nils Metzler-Nolte, Stefan Wölfl, Gilles Gasser.   

Abstract

The photophysical properties of [Re(CO)3 (L-N3)]Br (L-N3 =2-azido-N,N-bis[(quinolin-2-yl)methyl]ethanamine), which could not be localized in cancer cells by fluorescence microscopy, have been revisited in order to evaluate its use as a luminescent probe in a biological environment. The Re(I) complex displays concentration-dependent residual fluorescence besides the expected phosphorescence, and the nature of the emitting excited states have been evaluated by DFT and time-dependent (TD) DFT methods. The results show that fluorescence occurs from a (1) LC/MLCT state, whereas phosphorescence mainly stems from a (3) LC state, in contrast to previous assignments. We found that our luminescent probe, [Re(CO)3 (L-N3)]Br, exhibits an interesting cytotoxic activity in the low micromolar range in various cancer cell lines. Several biochemical assays were performed to unveil the cytotoxic mechanism of the organometallic Re(I) bisquinoline complex. [Re(CO)3 (L-N3)]Br was found to be stable in human plasma indicating that [Re(CO)3 (L-N3)]Br itself and not a decomposition product is responsible for the observed cytotoxicity. Addition of [Re(CO)3 (L-N3)]Br to MCF-7 breast cancer cells grown on a biosensor chip micro-bioreactor immediately led to reduced cellular respiration and increased glycolysis, indicating a large shift in cellular metabolism and inhibition of mitochondrial activity. Further analysis of respiration of isolated mitochondria clearly showed that mitochondrial respiratory activity was a direct target of [Re(CO)3 (L-N3)]Br and involved two modes of action, namely increased respiration at lower concentrations, potentially through increased proton transport through the inner mitochondrial membrane, and efficient blocking of respiration at higher concentrations. Thus, we believe that the direct targeting of mitochondria in cells by [Re(CO)3 (L-N3)]Br is responsible for the anticancer activity.
Copyright © 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  anticancer compounds; bioorganometallic chemistry; inorganic chemical biology; luminescence; medicinal organometallic chemistry; rhenium

Mesh:

Substances:

Year:  2014        PMID: 24464824     DOI: 10.1002/chem.201304012

Source DB:  PubMed          Journal:  Chemistry        ISSN: 0947-6539            Impact factor:   5.236


  15 in total

1.  Organometallic rhenium tricarbonyl-enrofloxacin and -levofloxacin complexes: synthesis, albumin-binding, DNA-interaction and cell viability studies.

Authors:  Chaido-Christina Pagoni; Vasiliki-Styliani Xylouri; Georgios C Kaiafas; Marialena Lazou; Georgia Bompola; Evangelos Tsoukas; Lefkothea C Papadopoulou; George Psomas; Dionysia Papagiannopoulou
Journal:  J Biol Inorg Chem       Date:  2019-05-20       Impact factor: 3.358

2.  In Vitro Anticancer Activity and in Vivo Biodistribution of Rhenium(I) Tricarbonyl Aqua Complexes.

Authors:  Kevin M Knopf; Brendan L Murphy; Samantha N MacMillan; Jeremy M Baskin; Martin P Barr; Eszter Boros; Justin J Wilson
Journal:  J Am Chem Soc       Date:  2017-09-26       Impact factor: 15.419

3.  Mitochondria-targeted Re(I) complexes bearing guanidinium as ligands and their anticancer activity.

Authors:  Shu-Fen He; Nan-Lian Pan; Bing-Bing Chen; Jia-Xin Liao; Min-Ying Huang; Hai-Jun Qiu; Dong-Chun Jiang; Jun-Jie Wang; Jia-Xi Chen; Jing Sun
Journal:  J Biol Inorg Chem       Date:  2020-10-20       Impact factor: 3.358

4.  Necroptosis-inducing rhenium(V) oxo complexes.

Authors:  Kogularamanan Suntharalingam; Samuel G Awuah; Peter M Bruno; Timothy C Johnstone; Fang Wang; Wei Lin; Yao-Rong Zheng; Julia E Page; Michael T Hemann; Stephen J Lippard
Journal:  J Am Chem Soc       Date:  2015-02-20       Impact factor: 15.419

5.  In Vivo Anticancer Activity of a Rhenium(I) Tricarbonyl Complex.

Authors:  Chilaluck C Konkankit; A Paden King; Kevin M Knopf; Teresa L Southard; Justin J Wilson
Journal:  ACS Med Chem Lett       Date:  2019-04-23       Impact factor: 4.345

6.  Enhanced Cytotoxicity through Conjugation of a "Clickable" Luminescent Re(I) Complex to a Cell-Penetrating Lipopeptide.

Authors:  Anna Leonidova; Vanessa Pierroz; Luke A Adams; Nicholas Barlow; Stefano Ferrari; Bim Graham; Gilles Gasser
Journal:  ACS Med Chem Lett       Date:  2014-05-15       Impact factor: 4.345

7.  Resistance-breaking profiling and gene expression analysis on an organometallic ReI-phenanthridine complex reveal parallel activation of two apoptotic pathways.

Authors:  Marcel König; Daniel Siegmund; Lukasz J Raszeja; Aram Prokop; Nils Metzler-Nolte
Journal:  Medchemcomm       Date:  2017-12-20       Impact factor: 3.597

8.  Crystal structure of hexa-aqua-nickel(II) bis{2-[(5,6-di-hy-droxy-3-sul-fon-ato-quino-lin-1-ium-7-yl)oxy]acetate} dihydrate.

Authors:  Hai Le Thi Hong; Vinh Nguyen Thi Ngoc; Da Tran Thi; Ngan Nguyen Bich; Luc Van Meervelt
Journal:  Acta Crystallogr E Crystallogr Commun       Date:  2015-08-26

9.  A TrxR inhibiting gold(I) NHC complex induces apoptosis through ASK1-p38-MAPK signaling in pancreatic cancer cells.

Authors:  Xinlai Cheng; Palvo Holenya; Suzan Can; Hamed Alborzinia; Riccardo Rubbiani; Ingo Ott; Stefan Wölfl
Journal:  Mol Cancer       Date:  2014-09-25       Impact factor: 27.401

Review 10.  Nanoparticles Functionalised with Re(I) Tricarbonyl Complexes for Cancer Theranostics.

Authors:  Marcus Mkhatshwa; Joshua Mamolatelo Moremi; Katlego Makgopa; Amanda-Lee Ezra Manicum
Journal:  Int J Mol Sci       Date:  2021-06-18       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.